GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, capital-management
TL;DR
GSK bought back some of its own stock on 9/3/25 via Merrill Lynch.
AI Summary
GSK plc announced on September 3, 2025, that it purchased a certain number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing details a transaction in the company's own shares.
Why It Matters
This filing indicates GSK is actively managing its share capital, potentially signaling confidence in its valuation or a strategy to return capital to shareholders.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share repurchases and does not present new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker executing share purchases
- September 3, 2025 (date) — Date of share purchase announcement
FAQ
What specific number of GSK ordinary shares were purchased?
The filing states that a 'certain number' of ordinary shares were purchased, but the exact quantity is not specified in the provided text.
What was the price per share for these repurchases?
The filing does not disclose the price per share at which the ordinary shares were purchased.
What is the purpose of GSK's share repurchase program?
The filing does not explicitly state the purpose of the share repurchase, but such actions can be related to capital management or returning value to shareholders.
Is this a new share repurchase program or an ongoing one?
The filing indicates a 'Transaction in own shares' and does not specify if it's a new or ongoing program.
Does this transaction affect the number of outstanding shares?
Yes, the repurchase of own shares typically reduces the number of outstanding shares.
Filing Stats: 2,911 words · 12 min read · ~10 pages · Grade level 3.4 · Accepted 2025-09-03 06:52:05
Filing Documents
- a7292x.htm (6-K) — 2452KB
- 0001654954-25-010336.txt ( ) — 2453KB
From the Filing
IN OWN SHARES a7292x   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of September 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   02 September 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   296,202   Lowest price paid per share (GBp):   1,440.50p   Highest price paid per share (GBp):   1,469.00p   Volume-weighted average price paid per share (GBp):   1,450.10p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 26,797,755 ordinary shares.   Following the above purchase, the Company will hold 244,932,138 ordinary shares in treasury and have 4,070,463,958 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,070,463,958. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.02 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     02 September 2025   Investment firm:        Merrill Lynch International Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   296,202   1,469.00p   1,440.50p   1,450.10p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -     Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   51   1,444.50    XLON   02-Sep-2025   08:00:22   0XL06140000000005MJ74U   52   1,444.50    XLON   02-Sep-2025   08:00:22   0XL06170000000005MJ77C   53   1,444.50    XLON   02-Sep-2025   08:00:22   0XL06110000000005MJ75P   54   1,444.50    XLON   02-Sep-2025   08:00:22   0XL06110000000005MJ75O   54   1,444.50    XLON   02-Sep-2025   08:00:22   0XL06170000000005MJ77B   733   1,444.50    XLON   02-Sep-2025   08:00:22   0XL06A00000000005MJ72J   8,008   1,443.50    XLON   02-Sep-2025   08:00:32   0XL06A00000000005MJ75D   39   1,443.00    XLON   02-Sep-2025   08:00:34   0XL06110000000005MJ78Q